Dare Bioscience, Inc. (DARE) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Dare Bioscience, Inc. is a biopharmaceutical company focused on women's health, with a portfolio including the FDA-approved product XACIATO (commercialized by Organon) and several clinical-stage candidates such as Ovaprene (contraception) and Sildenafil Cream (female sexual arousal disorder). The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Total Revenue | $22,438 | $31,740 | $0 |
| Net Income (Loss) | $12,910,656 | $6,155,300 | $(16,804,733) |
| Operating Loss | $(7,359,466) | $(13,381,939) | $(17,372,005) |
| Operating Expenses | $7,381,904 | $13,413,679 | $17,372,005 |
| Cash and Cash Equivalents | $16,414,992 (as of June 30, 2024) | ||
| Working Capital | ~$6.2 million | ||
| Accumulated Deficit | $(165.1 million) |
Other Income: The company recorded a one-time gain of approximately $20.4 million (net of transaction costs) from the sale of future royalty and milestone rights to XOMA in April 2024. This non-operating item drove the net income for the period.
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net income of $12.9 million for Q2 2024, a significant turnaround from a net loss of $8.8 million in Q2 2023. This is primarily attributable to the $20.4 million gain on the sale of royalty rights, not operational performance.
- Operating Expenses: Total operating expenses decreased by 18% in Q2 2024 compared to Q2 2023 ($7.4M vs $9.0M). Research and Development (R&D) expenses declined by 19% ($4.9M vs $6.0M), driven by the completion of the Phase 2b study for Sildenafil Cream and reduced spending on preclinical programs.
- Cash Flow: Net cash provided by operating activities was $6.1 million for the six months ended June 30, 2024, compared to a use of $22.7 million in the same period in 2023. The improvement is largely due to the royalty sale proceeds and a decrease in prepaid expenses.
- Stock Structure: A 1-for-12 reverse stock split was effected on July 1, 2024. All share data in this report has been retroactively adjusted to reflect this split.
Guidance, Outlook, and Risks
- Going Concern Warning: Management explicitly states that the company does not have sufficient cash to satisfy working capital needs for the next 12 months. Substantial additional capital is required to continue operations and development programs.
- Development Focus: Until additional capital is secured, the company will focus resources primarily on the pivotal Phase 3 trial of Ovaprene and advancing Sildenafil Cream toward Phase 3. Other programs will be scaled back.
- Royalty Monetization: The company sold 100% of future royalties and milestones from XACIATO sales to XOMA. Future income from XACIATO is contingent on XOMA receiving payments exceeding $88 million, at which point Dare would receive 50% of subsequent payments.
- Nasdaq Compliance: On August 12, 2024, the company received notice of non-compliance with the Nasdaq Minimum Market Value of Listed Securities (MVLS) requirement of $35.0 million. The company has 180 days (until February 10, 2025) to regain compliance.
- Grant Funding: The company relies on non-dilutive grants (e.g., from the Bill & Melinda Gates Foundation and NICHD) to fund specific programs like DARE-LARC1. As of June 30, 2024, deferred grant funding liabilities totaled approximately $10.9 million.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to raise capital given the explicit "substantial doubt" regarding going concern status and the $16.4 million cash balance.
- Nasdaq Listing Status: Monitor the company's progress in regaining compliance with the $35 million Market Value of Listed Securities requirement by February 2025 to avoid delisting.
- XACIATO Royalty Terms: Review the specific thresholds ($88 million) required for Dare to receive any future upside from XACIATO sales after the XOMA transaction.
- Ovaprene Phase 3 Progress: Track enrollment and data readouts for the pivotal Phase 3 contraceptive trial, which is the primary near-term catalyst.
- Grant Utilization: Confirm that grant funds (approx. $10.9M deferred liability) are being utilized efficiently for their designated programs (DARE-LARC1, DARE-LBT) and do not cover general overhead beyond the allowed 10%.